Denali Therapeutics Inc. Expense Breakdown
No Expense Breakdown for DNLI on this site yet.
- 2026-06-30: Therapeutics $134.15M.
- 2025-06-30: Therapeutics $134.96M.
Source checked: the stored Expense Breakdown page for DNLI.
Expenses by product
Costs and Expenses: each quarter (3 month)
| Quarter end | Therapeutics |
|---|---|
| 2026-06-30 | $134.15M |
| 2025-06-30 | $134.96M |
Research and development: each quarter (3 month)
| Quarter end | Therapeutics |
|---|---|
| 2026-06-30 | $97.02M |
| 2025-06-30 | $102.70M |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Therapeutics |
|---|---|
| 2026-06-30 | $36.28M |
| 2025-06-30 | $32.27M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |